Fig. 7

qilin genetically interacts with ift172 and ift27.

(A–B) Side view of a representative uninjected control embryo (A) and a phenotypic embryo injected with qilin and/or ift172, ift27 morpholino (B) at 2 dpf. (C, D) Graph displaying the percent of embryos that develop curved bodies. In C, embryos are either injected with qilin morpholino and the control morpholino; ift172 morpholino and the control morpholino; or qilin morpholino with ift172 morpholino. In D, embryos are either injected with qilin morpholino and the ift27 mismatched-control morpholino; ift27 morpholino and the ift27 mismatched-control morpholino; or qilin morpholino with ift27 morpholino. (E–G)Graphical representation of the effectiveness of ift27:GFP in rescuing body curvature (E), kidney cysts (F), and laterality defects (G) observed in ift27 morphants. Embryos are either injected with ift27 morpholino and myc:GFP mRNA (blue bars), or ift27 morpholino with ift27:GFP mRNA (pink bars). Laterality defects in (G) is presented as the percentage of embryos developed hearts positioned on the right or center. N = 3 for all experiments, with at least 40 embryos per experiment per condition. *: p< 0.05, **: p< 0.01. MO: morpholino.